Total amount raised
$25 Millions
Latest funding date
07/01/2022
Location
Title
Kernal Biologics has successfully raised significant funding over multiple rounds, attracting a diverse group of investors. The company is pioneering mRNA-based therapies with a focus on oncology and immunology.
Keep reading to explore the intricacies of Kernal Biologics' fundraising journey and the investors backing this innovative platform.
What Is Kernal Biologics?
Kernal Biologics, founded in 2018, is based in Cambridge, MA. The company specializes in mRNA technology, focusing on oncology and immunology.
They develop mRNA 2.0 technology, which involves intelligently programmed mRNA that is precisely delivered and selectively translated in target cells. This innovative approach aims to set new standards in therapeutic care.
While the exact number of employees and the founders' names are not specified, Kernal Biologics continues to grow and make significant strides in the biotech industry.
How Much Funding Has Kernal Biologics Raised?
- Series A Financing
- Amount Raised: $25 million
- Date: July 2022
- Lead Investors: Hummingbird Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: The funds will be used to extend Kernal Biologics' mRNA 2.0 platform and support the filing of an IND for their immuno-oncology candidate KR-335.
Kernal Biologics has raised a total of $25 million. The current valuation is not publicly disclosed.
Key Investors
- Hummingbird Ventures
- Details: Hummingbird Ventures is a venture capital firm that led the Series A financing round for Kernal Biologics. Firat Ileri, Managing Partner, has joined the board of Kernal Biologics.
- Investment Focus Areas: Early-stage technology companies, healthcare, biotechnology.
- Notable Investments: Peak Games, Showpad, Deliveroo.
- Amgen Ventures
- Details: Amgen Ventures is the corporate venture capital arm of Amgen Inc., focusing on investments in biotechnology and life sciences. They participated in the Series A financing round for Kernal Biologics.
- Investment Focus Areas: Biotechnology, life sciences, healthcare.
- Notable Investments: Atara Biotherapeutics, Precision BioSciences, Replimune.
- HBM Genomics
- Details: HBM Genomics is a venture capital firm specializing in investments in genomics and related fields. They participated in the Series A financing round for Kernal Biologics.
- Investment Focus Areas: Genomics, biotechnology, healthcare.
- Notable Investments: 23andMe, Illumina, Pacific Biosciences.
- Civilization Ventures
- Details: Civilization Ventures is a venture capital firm that invests in transformative life sciences and healthcare technologies. They participated in the Series A financing round for Kernal Biologics.
- Investment Focus Areas: Life sciences, healthcare, biotechnology.
- Notable Investments: Freenome, Recursion Pharmaceuticals, Verge Genomics.
What's Next for Kernal Biologics?
With the recent $25 million Series A financing, Kernal Biologics is poised to expand its mRNA 2.0 platform and file an IND for their immuno-oncology candidate KR-335. This opportunity could significantly impact the mRNA technology and cancer therapeutics market, offering new avenues for growth and collaboration with global pharma companies.
Future fundraising seems promising, given the strong backing from high-profile investors. However, the company may face regulatory hurdles and intense competition in the mRNA and oncology sectors. Ensuring the efficacy and uniqueness of their mRNA technology will be crucial for their continued success.
Use Clay to Get Funding Data
Sales professionals, take advantage of Clay's platform to access comprehensive fundraising data on companies like Kernal Biologics and gather other critical business insights.
Sign up for free on Clay and elevate your sales strategy today.
